-
Something wrong with this record ?
Synthesis of cytotoxic 2,2-difluoroderivatives of dihydrobetulinic acid and allobetulin and study of their impact on cancer cells
L. Borkova, L. Jasikova, J. Rehulka, K. Frisonsova, M. Urban, I. Frydrych, I. Popa, M. Hajduch, NJ. Dickinson, M. Vlk, P. Dzubak, J. Sarek,
Language English Country France
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Apoptosis drug effects MeSH
- Cell Cycle drug effects MeSH
- Fibroblasts drug effects MeSH
- Hydrocarbons, Fluorinated chemical synthesis chemistry pharmacology MeSH
- Antineoplastic Agents, Phytogenic chemical synthesis chemistry pharmacology MeSH
- Humans MeSH
- Molecular Conformation MeSH
- Tumor Cells, Cultured MeSH
- Cell Proliferation drug effects MeSH
- Drug Screening Assays, Antitumor MeSH
- Triterpenes chemistry MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
In this article, we describe the preparation and cytotoxic properties of a small focused library of lupane and 18α-oleanane triterpenoids that contain a combination of two structural motifs known to enhance the biological activities. First, we introduced two fluorine atoms to position 2 of the skeleton. Second, we synthesized a set of hemiester prodrugs, which were intended to increase the solubility and activity. Starting from betulin, we obtained two hydroxyketones (derivatives of dihydrobetulinic acid and allobetulin) and their fluorination using DAST provided 2,2-difluoro-3-oxo-compounds as the main products. Then the 3-oxo group in each derivative was reduced by NaBH4 to obtain 3β-hydroxy compounds suitable for modifying by various hemiesters. We prepared 21 compounds, 11 of them new, their cytotoxicity was tested on T lymphoblastic leukemia CCRF-CEM cells first and the most active derivatives were selected for screening on another six tumor and two non-tumor cell lines. All of them showed selectivity against cancer lines with therapeutic index between 2 and 8. All hemiesters had activity in the same range as the free hydroxyl derivatives and they would be suitable prodrugs for future in vivo experiments. Interestingly, all hemiesters of 2,2-difluorodihydrobetulonic acid had higher activity against p53 knock-out p53-/- cancer cell line than against the non-mutated analog. In active derivatives, the cell cycle was analyzed by flow cytometry and several compounds slowed down cell cycle progression through G0/G1 or S-phase.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010233
- 003
- CZ-PrNML
- 005
- 20200728084034.0
- 007
- ta
- 008
- 160408s2015 fr f 000 0|engg|
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2015.03.068 $2 doi
- 024 7_
- $a 10.1016/j.ejmech.2015.03.068 $2 doi
- 035 __
- $a (PubMed)25942059
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Borkova, Lucie $u Department of Organic Chemistry, Faculty of Science, Palacky University Olomouc, 17. listopadu 1192/12, 771 46 Olomouc, Czech Republic.
- 245 10
- $a Synthesis of cytotoxic 2,2-difluoroderivatives of dihydrobetulinic acid and allobetulin and study of their impact on cancer cells / $c L. Borkova, L. Jasikova, J. Rehulka, K. Frisonsova, M. Urban, I. Frydrych, I. Popa, M. Hajduch, NJ. Dickinson, M. Vlk, P. Dzubak, J. Sarek,
- 520 9_
- $a In this article, we describe the preparation and cytotoxic properties of a small focused library of lupane and 18α-oleanane triterpenoids that contain a combination of two structural motifs known to enhance the biological activities. First, we introduced two fluorine atoms to position 2 of the skeleton. Second, we synthesized a set of hemiester prodrugs, which were intended to increase the solubility and activity. Starting from betulin, we obtained two hydroxyketones (derivatives of dihydrobetulinic acid and allobetulin) and their fluorination using DAST provided 2,2-difluoro-3-oxo-compounds as the main products. Then the 3-oxo group in each derivative was reduced by NaBH4 to obtain 3β-hydroxy compounds suitable for modifying by various hemiesters. We prepared 21 compounds, 11 of them new, their cytotoxicity was tested on T lymphoblastic leukemia CCRF-CEM cells first and the most active derivatives were selected for screening on another six tumor and two non-tumor cell lines. All of them showed selectivity against cancer lines with therapeutic index between 2 and 8. All hemiesters had activity in the same range as the free hydroxyl derivatives and they would be suitable prodrugs for future in vivo experiments. Interestingly, all hemiesters of 2,2-difluorodihydrobetulonic acid had higher activity against p53 knock-out p53-/- cancer cell line than against the non-mutated analog. In active derivatives, the cell cycle was analyzed by flow cytometry and several compounds slowed down cell cycle progression through G0/G1 or S-phase.
- 650 _2
- $a fytogenní protinádorové látky $x chemická syntéza $x chemie $x farmakologie $7 D000972
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 _2
- $a buněčný cyklus $x účinky léků $7 D002453
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a screeningové testy protinádorových léčiv $7 D004354
- 650 _2
- $a fibroblasty $x účinky léků $7 D005347
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a fluorované uhlovodíky $x chemická syntéza $x chemie $x farmakologie $7 D006845
- 650 _2
- $a molekulární konformace $7 D008968
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a triterpeny $x chemie $7 D014315
- 650 _2
- $a nádorové buňky kultivované $7 D014407
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Jasikova, Lucie $u Department of Organic and Nuclear Chemistry, Faculty of Science, Charles University in Prague, Hlavova 8, 128 43 Prague 2, Czech Republic.
- 700 1_
- $a Rehulka, Jiri $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 5, 779 00 Olomouc, Czech Republic.
- 700 1_
- $a Frisonsova, Katerina $u Department of Organic and Nuclear Chemistry, Faculty of Science, Charles University in Prague, Hlavova 8, 128 43 Prague 2, Czech Republic.
- 700 1_
- $a Urban, Milan $u Department of Organic Chemistry, Faculty of Science, Palacky University Olomouc, 17. listopadu 1192/12, 771 46 Olomouc, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 5, 779 00 Olomouc, Czech Republic. $7 xx0117688
- 700 1_
- $a Frydrych, Ivo $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 5, 779 00 Olomouc, Czech Republic.
- 700 1_
- $a Popa, Igor $u Department of Organic Chemistry, Faculty of Science, Palacky University Olomouc, 17. listopadu 1192/12, 771 46 Olomouc, Czech Republic.
- 700 1_
- $a Hajduch, Marian $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 5, 779 00 Olomouc, Czech Republic.
- 700 1_
- $a Dickinson, Niall J $u Department of Organic Chemistry, Faculty of Science, Palacky University Olomouc, 17. listopadu 1192/12, 771 46 Olomouc, Czech Republic.
- 700 1_
- $a Vlk, Martin $u Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Brehova 7, 115 19 Prague 1, Czech Republic.
- 700 1_
- $a Dzubak, Petr $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 5, 779 00 Olomouc, Czech Republic. Electronic address: dzubakp@gmail.com.
- 700 1_
- $a Sarek, Jan $u Department of Organic Chemistry, Faculty of Science, Palacky University Olomouc, 17. listopadu 1192/12, 771 46 Olomouc, Czech Republic; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 5, 779 00 Olomouc, Czech Republic. Electronic address: jan.sarek@gmail.com.
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 96, č. - (2015), s. 482-90
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25942059 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20200728084031 $b ABA008
- 999 __
- $a ok $b bmc $g 1113662 $s 934601
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 96 $c - $d 482-90 $e 20150401 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- LZP __
- $a Pubmed-20160408
